SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
OXiGENE Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT® in Anaplastic Thyroid Cancer